Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings per share of ($0.87) for the quarter, down from their previous forecast of ($0.84). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.13) per share. Wedbush also issued estimates for Xenon Pharmaceuticals' Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.94) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.68) EPS, FY2026 earnings at ($4.23) EPS, FY2027 earnings at ($3.43) EPS and FY2028 earnings at $1.42 EPS.
A number of other equities analysts have also commented on the stock. Raymond James reaffirmed an "outperform" rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Needham & Company LLC reiterated a "buy" rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $56.00.
Check Out Our Latest Stock Analysis on XENE
Xenon Pharmaceuticals stock opened at $39.95 on Monday. Xenon Pharmaceuticals has a fifty-two week low of $35.53 and a fifty-two week high of $50.99. The firm's 50 day simple moving average is $40.20 and its 200-day simple moving average is $40.82. The company has a market cap of $3.05 billion, a P/E ratio of -14.17 and a beta of 1.20.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.01. During the same period in the previous year, the firm posted ($0.73) earnings per share.
In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary Patou sold 4,891 shares of the firm's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the transaction, the director now owns 23,573 shares in the company, valued at $968,378.84. This represents a 17.18 % decrease in their position. The disclosure for this sale can be found here. 5.52% of the stock is owned by corporate insiders.
Large investors have recently bought and sold shares of the business. Blue Trust Inc. boosted its stake in shares of Xenon Pharmaceuticals by 174.7% during the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 641 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in Xenon Pharmaceuticals in the 4th quarter worth approximately $101,000. nVerses Capital LLC bought a new stake in Xenon Pharmaceuticals during the third quarter worth approximately $102,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock valued at $106,000 after purchasing an additional 487 shares during the last quarter. Finally, KBC Group NV raised its position in shares of Xenon Pharmaceuticals by 39.8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 780 shares during the period. 95.45% of the stock is currently owned by institutional investors.
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.